title: Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group.
abstract: OBJECTIVE
  The early stages of mycosis fungoides (MF) can be treated but not cured by photochemotherapy (PUVA) alone; some recent studies of the effect of a combination of human interferon-alpha (IFN(alpha)) and PUVA reported a high degree of response. The aim of our study was to evaluate the activity of a low dose of IFN-alpha2b combined with PUVA.
  
  
  METHODS
  Twenty-five patients were included: 16 men and 9 women aged between 23-80 years; 19 patients ahd stage I and 6 stage II disease. In the induction phase, the dose of IFNalpha was gradually raised over 6-8 weeks to the target dose of 18 MU/week; in the maintenance phase, the combination with PUVA allowed IFNalpha to be reduced to a maximum dose of 6 MU/week; in this way the cumulative administration of IFNalpha and PUVA was considerably lower than in similar combination protocols. Treatment success was analyzed in terms of freedom from treatment failure (FFTF).
  
  
  RESULTS
  After the induction phase 9/25 patients (36%) achieved complete remission (CR) and 15/25 (56%) achieved partial remission (PR). One to five months from the beginning of the maintenance phase, a CR was recorded in 19/25 patients (76%) and a PR in 5/25 patients (20%) accounting for an overall response rate of 96%. The median of FFTF was not reached; probability of FFTF was 82% at 12 months and 62% at 24 months. Disease free survival projected to 48 months was 75%.
  
  
  CONCLUSIONS
  Even with low doses of IFNalpha plus PUVA it is possible to achieve excellent clinical responses,many of which are long-lasting, in patients with early MF.
authors.affiliation: Clinica di Ematologia Ospedale Generale Regionale 60020, Torrette di Ancona, Italy. clinemat@popcsi.unian.it
authors.forename: S
authors.initials: S
authors.lastname: Rupoli
authors.forename: S
authors.initials: S
authors.lastname: Barulli
authors.forename: B
authors.initials: B
authors.lastname: Guiducci
authors.forename: M
authors.initials: M
authors.lastname: Offidani
authors.forename: G
authors.initials: G
authors.lastname: Mozzicafreddo
authors.forename: M
authors.initials: M
authors.lastname: Simonacci
authors.forename: G
authors.initials: G
authors.lastname: Filosa
authors.forename: A
authors.initials: A
authors.lastname: Giacchetti
authors.forename: G
authors.initials: G
authors.lastname: Ricotti
authors.forename: G
authors.initials: G
authors.lastname: Brandozzi
authors.forename: I
authors.initials: I
authors.lastname: Cataldi
authors.forename: S
authors.initials: S
authors.lastname: Serresi
authors.forename: R
authors.initials: R
authors.lastname: Ceschini
authors.forename: L
authors.initials: L
authors.lastname: Bugatti
authors.forename: A
authors.initials: A
authors.lastname: Offidani
authors.forename: M
authors.initials: M
authors.lastname: Giangiacomi
authors.forename: D
authors.initials: D
authors.lastname: Brancorsini
authors.forename: P
authors.initials: P
authors.lastname: Leoni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011701:PUVA Therapy; D011446:Prospective Studies; D011994:Recombinant Proteins; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins